On August 22, 2022 RS Research, a clinical-stage biotechnology start-up developing smart nanomedicines for targeted chemotherapy, reported the acceptance of a poster presentation at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) 2022 Congress to be held in person on 9-13 September 2022 in Paris – France (Press release, RS Research, AUG 22, 2022, View Source [SID1234618595]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Title: Phase Ia/Ib study of RS-0139, a novel tumor-targeted delivery of docetaxel, in patients with recurrent, locally advanced, or metastatic non-small cell lung cancer (NSCLC)

Presenter: Prof. Dr. Hakan S. Orer, Medical Pharmacology, Koc University Hospital; Dr. Gülşah Nomak, Medical Director, RS Research

The poster will be published online via the ESMO (Free ESMO Whitepaper) website on 5 September 2022.